Novartis (NYSE:NVS) lifted the curtain on its 20252030 outlook on Thursday, projecting steady annual sales growth of 56% as ...

Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4 ...